The first head-to-head trial between two oral GLP-1 receptor agonists has concluded. Orforglipron, Eli Lilly's small-molecule GLP-1 agonist, outperformed oral semaglutide across both glycemic control and weight loss endpoints in the 52-week ACHIEVE-3 trial.
The results, published in The Lancet on February 26, 2026, showed orforglipron 36mg reduced A1C by 2.2% compared to 1.4% for oral semaglutide 14mg. Weight loss was 19.7 lbs with orforglipron versus 11.0 lbs with oral semaglutide, a 73.6% greater relative reduction.
These numbers matter because oral semaglutide, marketed as Rybelsus, represented a breakthrough in GLP-1 delivery when it launched in 2019. Getting a peptide to work orally required pharmaceutical engineering that cost Novo Nordisk years and hundreds of millions in development. Orforglipron doesn't just match that achievement. It beats it, with a simpler dosing protocol and no food restrictions.
But the safety profile raises questions. Discontinuation rates due to adverse events were higher with orforglipron. The drug works better but tolerability might limit its clinical utility. The FDA is expected to make a decision on orforglipron for obesity in Q2 2026, and these ACHIEVE-3 results will weigh heavily.
The Trial Design
ACHIEVE-3 was a 52-week, randomized, open-label, active-controlled Phase 3 trial conducted across 164 sites in the United States, Argentina, China, Japan, Mexico, and Puerto Rico. Open-label means participants and investigators knew which treatment was assigned, a design choice that reflects the practical differences in dosing protocols between the drugs (more on that shortly).
The trial enrolled 1,698 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. Baseline A1C averaged 8.3%, and baseline weight averaged around 200-220 lbs depending on treatment arm. This is a typical population for GLP-1 trials: established diabetes, metabolic dysfunction, overweight or obese.
Four arms:
- Orforglipron 12mg daily
- Orforglipron 36mg daily
- Oral semaglutide 7mg daily
- Oral semaglutide 14mg daily
The dose escalation schedules differed by drug but followed protocols designed to minimize gastrointestinal side effects, a universal challenge with GLP-1 receptor agonists.
The primary endpoint was change in A1C from baseline to week 52. Secondary endpoints included proportion of participants achieving A1C below 7% (the standard diabetes management target), weight change, and various cardiovascular risk markers.
Lead investigator Dr. Julio Rosenstock, from UT Southwestern Medical Center, has been involved in dozens of diabetes drug trials and is one of the most cited researchers in GLP-1 pharmacology. His involvement signals the trial's credibility within the field.
Glycemic Control: Orforglipron's Clear Advantage
At 52 weeks, orforglipron 36mg reduced A1C by 2.2 percentage points from a baseline of 8.3%. Oral semaglutide 14mg reduced it by 1.4 points. That's a statistically and clinically significant difference.
The proportion of participants achieving A1C below 7% was 85.4% with orforglipron 36mg versus 66.1% with oral semaglutide 14mg. The lower dose of orforglipron (12mg) produced A1C reductions of 1.8%, still better than the high-dose oral semaglutide.
To put this in context, A1C reductions of 1.5% or greater are considered robust efficacy for diabetes drugs. A 2.2% reduction from a starting point of 8.3% brings average glucose levels well into the normal range. This isn't incremental improvement. It's disease control that approaches what injectable semaglutide and tirzepatide achieve.
The mechanism here is GLP-1 receptor activation. Both drugs bind the same receptor, stimulating insulin secretion in response to glucose, suppressing glucagon release, and slowing gastric emptying. The superior performance of orforglipron likely reflects higher effective receptor occupancy, possibly from better bioavailability or pharmacokinetic profile.
Oral semaglutide's absorption is limited even with the SNAC absorption enhancer it's co-formulated with. Absolute bioavailability is around 1% compared to subcutaneous semaglutide. Orforglipron, as a small molecule rather than a peptide, may achieve higher oral bioavailability, though Lilly hasn't published detailed pharmacokinetic data comparing the two.
What the trial demonstrates clearly is that small-molecule GLP-1 agonists can outperform peptide-based versions when delivered orally. This has been a goal of pharmaceutical development for over a decade. Orforglipron is the first to achieve it in a head-to-head trial.
Weight Loss: 73.6% Greater Reduction
Orforglipron 36mg produced an average weight loss of 19.7 lbs (9.2% of body weight) over 52 weeks. Oral semaglutide 14mg resulted in 11.0 lbs lost (5.3% body weight).
The relative difference, 73.6% greater weight loss with orforglipron, is the kind of number that gets attention in metabolic medicine. GLP-1 drugs have reshaped obesity treatment precisely because they produce this level of weight reduction without requiring extreme caloric restriction or intensive behavioral intervention. Doubling the effect size compared to an already effective drug changes the clinical calculus.
For context, the weight loss seen with orforglipron 36mg approaches what injectable semaglutide 2.4mg (Wegovy) achieves in obesity trials, typically around 10-15% body weight over 68 weeks. It's less than what tirzepatide produces (15-22% depending on dose) but significantly more than first-generation GLP-1 drugs like liraglutide (5-7%) or oral semaglutide.
The mechanism driving weight loss with GLP-1 agonists involves several pathways. Central appetite suppression through hypothalamic GLP-1 receptors reduces food intake. Delayed gastric emptying increases satiety. Alterations in reward processing in the brain may reduce hedonic eating. The net effect is sustained caloric deficit without the overwhelming hunger that typically undermines weight loss efforts.
Whether orforglipron's superior weight loss comes from higher receptor activation, better CNS penetration, or some other pharmacological difference remains unclear. What's clear is the outcome: patients on orforglipron lost significantly more weight than those on oral semaglutide.
Cardiovascular Risk Factors
The trial also tracked changes in lipid profiles, blood pressure, and other cardiovascular risk markers. Results favored orforglipron across multiple parameters:
Non-HDL cholesterol decreased more with orforglipron 36mg than oral semaglutide 14mg. Non-HDL is considered a better predictor of cardiovascular risk than LDL alone because it captures all atherogenic lipoproteins.
HDL cholesterol increased with orforglipron, a favorable change associated with reduced cardiovascular risk.
VLDL and total cholesterol both improved more with orforglipron.
Systolic blood pressure dropped by an additional 3-4 mmHg with orforglipron compared to oral semaglutide, a modest but meaningful reduction in hypertension.
Triglycerides decreased in both groups but showed greater reduction with orforglipron.
These aren't surrogate endpoints that always translate to clinical outcomes, but they're well-validated predictors. Diabetes patients face elevated cardiovascular risk, and drugs that improve glycemic control while simultaneously improving lipid profiles and blood pressure offer layered benefit.
The GLP-1 drug class as a whole has demonstrated cardiovascular benefits in large outcome trials. Semaglutide's SELECT trial showed a 20% reduction in major adverse cardiovascular events in non-diabetic obese patients. Whether orforglipron produces similar or superior cardiovascular outcomes will require dedicated long-term trials, but the favorable effects on risk factors suggest potential.
The Dosing Advantage
One of orforglipron's major differentiators is ease of use.
Oral semaglutide requires patients to take the pill on an empty stomach with no more than 4 oz of water, then wait 30 minutes before eating or drinking anything else. This fasting protocol is necessary to maximize the already-low 1% bioavailability. Miss the timing and absorption drops further.
For patients, this is a daily logistical challenge. You need to take it first thing in the morning before food or caffeine. If you forget, you can't just take it later with breakfast. The regimen demands discipline and routine that many patients struggle to maintain.
Orforglipron has no such restrictions. Take it any time of day, with or without food. This simplicity improves adherence, which directly impacts real-world effectiveness. A more potent drug that patients forget to take or take incorrectly loses its advantage. An easier-to-use drug that patients actually take consistently wins in clinical practice.
The open-label trial design makes sense in this context. You can't blind a study when one drug requires fasting and the other doesn't. Participants will know which they're taking based on the protocol. This introduces potential bias, but the magnitude of differences in efficacy outcomes makes bias an unlikely full explanation.
Orforglipron Is Not a Peptide
This matters more than it might seem.
Semaglutide is a modified GLP-1 peptide. It's a 31-amino-acid sequence with an albumin-binding side chain that extends its half-life. Getting peptides to survive oral administration is inherently difficult because the digestive system treats them as food. Proteases in the stomach and intestines break peptide bonds. What reaches circulation is usually fragments, not intact active drug.
Novo Nordisk solved this with SNAC, the absorption enhancer co-formulated with Rybelsus. SNAC increases local pH in the stomach and promotes absorption through the gastric wall. Even with this, bioavailability remains around 1%. You need a large dose to get enough drug into circulation.
Orforglipron is a small molecule, not a peptide. It was discovered by Chugai Pharmaceutical in Japan and licensed to Eli Lilly in 2018. Small molecules don't face the same digestive breakdown that peptides do. Oral bioavailability for small-molecule GLP-1 agonists can be significantly higher, potentially explaining orforglipron's superior performance.
This also has manufacturing and cost implications. Peptide synthesis is complex and expensive. Small-molecule synthesis is generally cheaper and more scalable. If orforglipron reaches market, production costs could be lower than semaglutide, potentially affecting pricing, though pharmaceutical pricing is driven by far more than manufacturing cost.
The broader point: orforglipron represents a different class of GLP-1 drugs. It's not just a better version of what exists. It's a structurally distinct approach that sidesteps the limitations inherent to peptide-based GLP-1 therapies.
Safety and Tolerability: The Other Side
Efficacy tells half the story. The other half is whether patients can tolerate the drug.
Discontinuation due to adverse events was 9.7% in the orforglipron 36mg group versus 4.9% in the oral semaglutide 14mg group. That's nearly double the dropout rate.
The most common adverse events were gastrointestinal: nausea, vomiting, diarrhea. This is universal with GLP-1 drugs. The mechanism that slows gastric emptying and promotes satiety also causes GI distress, especially during dose escalation.
The trial used a gradual dose ramp to minimize this, but even with careful titration, orforglipron produced more GI side effects than oral semaglutide. Whether this reflects the higher effective dose, different pharmacokinetics, or some intrinsic property of the molecule isn't clear from the published data.
For clinical use, a 9.7% discontinuation rate is acceptable if the drug works well for the 90% who stay on it. But it's a real limitation. Patients who can't tolerate orforglipron will need alternatives, and oral semaglutide, with its lower discontinuation rate, remains a viable option for those prioritizing tolerability over maximal efficacy.
Dr. Marie Spreckley from the University of Cambridge, commenting on the trial results, praised the efficacy data but flagged the discontinuation rates and the absence of long-term cardiovascular outcome data as important considerations. Her assessment is fair. The drug works, but safety monitoring and patient selection will matter.
The ACHIEVE Program Context
ACHIEVE-3 is one piece of a larger development program. The ACHIEVE program enrolled over 6,000 patients across five registrational trials designed to support orforglipron's approval for type 2 diabetes and obesity.
ACHIEVE-1 and ACHIEVE-2 examined orforglipron versus placebo in different diabetes populations. ACHIEVE-3 is the head-to-head against oral semaglutide. Additional trials explored combination therapy and longer-term outcomes.
Eli Lilly submitted orforglipron to regulatory authorities in over 40 countries. The FDA's decision on the obesity indication is expected in Q2 2026, likely sometime in April or May. If approved, orforglipron would join semaglutide and tirzepatide in the GLP-1 market, adding a third major player with a distinct profile.
The competitive dynamics are worth noting. Novo Nordisk dominates GLP-1 sales with Ozempic and Wegovy. Eli Lilly entered with tirzepatide (Mounjaro/Zepbound), a dual GLP-1/GIP agonist that produces even greater weight loss. Orforglipron gives Lilly a second GLP-1 asset, this one oral, filling a different niche.
For patients and practitioners, more options are better. Some patients prefer oral over injectable. Some tolerate one drug better than another. Some respond more robustly to specific formulations. A diverse GLP-1 portfolio allows personalized matching.
What This Means for the GLP-1 field
The ACHIEVE-3 results establish that oral GLP-1 therapy can exceed the efficacy of first-generation oral formulations and approach what injectable versions achieve.
Oral semaglutide was a breakthrough but also a compromise. You got the convenience of a pill but gave up some efficacy compared to the injection. Orforglipron changes that trade-off. You get the pill and you get efficacy that rivals or exceeds injectable GLP-1s.
This will likely accelerate the shift toward oral GLP-1 therapy in both diabetes and obesity treatment. Injections work, but many patients prefer to avoid them if an equally effective oral option exists. If orforglipron receives approval and payers cover it, uptake will be substantial.
The pharmaceutical industry is watching closely. Multiple companies have small-molecule GLP-1 programs in development. Pfizer's danuglipron, Roche's RG7697, and several others are in various stages of trials. ACHIEVE-3 proves the concept works. Expect intensified competition in this space over the next few years.
The obesity market specifically is enormous and growing. GLP-1 drugs are reshaping how obesity is treated, moving from lifestyle intervention and bariatric surgery toward pharmacotherapy as a primary tool. Effective oral options will expand access, particularly in populations wary of injections or lacking resources for cold-chain storage and sharps disposal.
The Limitations
The trial was 52 weeks. That's long enough to demonstrate efficacy and short-term safety but not long enough to assess durability or long-term adverse events. Cardiovascular outcomes require multi-year trials. Cancer risk, if any exists, won't show up in one year. Real-world effectiveness in less controlled settings may differ from trial results.
The open-label design introduces bias potential, though the objective nature of A1C and weight measurements limits this concern.
The population was people with type 2 diabetes on metformin. Results in different populations (newly diagnosed diabetes, pre-diabetes, obesity without diabetes) may vary.
And the discontinuation rate, while not disqualifying, is a real-world limitation that will affect which patients end up on orforglipron versus alternatives.
FDA Decision Looms
Eli Lilly's submission for obesity is pending. The FDA will weigh the efficacy data against the safety profile, compare it to available alternatives, and decide whether the benefit-risk balance justifies approval.
Given the obesity epidemic and the demonstrated efficacy in ACHIEVE-3 and other trials, approval seems likely. The question is what label restrictions or warnings the FDA might impose around GI tolerability or other safety concerns.
If approved, orforglipron will launch into a market already experiencing supply constraints and enormous demand. Wegovy and Zepbound face periodic shortages. Adding another effective oral option could ease some pressure, though manufacturing scale-up for a new drug takes time.
Pricing will also be a major question. GLP-1 drugs are expensive, typically $900-1,400 per month without insurance. If orforglipron prices comparably, insurance coverage and access will determine real-world impact. If Lilly prices it lower to gain market share, broader uptake becomes more feasible.
The next few months will clarify these questions. For now, the data is in: orforglipron works, it works better than oral semaglutide, and it represents the next evolution in oral GLP-1 therapy.